Evidence map›Paper›PMID 42401714›Full record

ArticleNPJ precision oncology2026

Integrated multiclass driver ctDNA profiling enables MPNST detection and monitoring in NF1 patients.

Paul A Jones, Aaron U Bektas, Jeffrey J Szymanski, R Taylor Sundby, John S A Chrisinger, Peter K Harris, Mark I Zoberi, Kara Weekley, Sanita Burgic, Stacey Chamberlain and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Paul A JonesDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Aaron U BektasDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Jeffrey J SzymanskiDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
R Taylor SundbyNemours Children's Health, Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Wilmington, DE, USA.
John S A ChrisingerDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Peter K HarrisDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Mark I ZoberiDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Kara WeekleyDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Sanita BurgicDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Stacey ChamberlainDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Faridi QaiumDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Jack F ShernPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. shern@nci.edu.
Aadel A ChaudhuriDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. Chaudhuri.Aadel@mayo.edu.
Angela C HirbeDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. hirbea@wustl.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed and internally cross-validated an integrated circulating tumor DNA assay incorporating single nucleotide variants (SNVs), insertions/deletions (indels), copy number alterations (CNAs), and structural variants (SVs) to distinguish neurofibromatosis type 1 patients with malignant peripheral nerve sheath tumors (MPNST) from those with benign plexiform neurofibromas and tumor-free controls. Among 82 participants, the assay achieved an AUC of 0.917 versus 0.737 for off-target genome-wide CNA analysis. We detected disease-specific alterations, relapse eighty days before diagnosis, and molecular clearance consistent with remission.

Identifiers

PMID42401714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.